StockData
SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

SANGAMO THERAPEUTICS, INC

Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026
$0.10−0.01 (-8.17%)

Close on Oct 19, 2026

Market cap
$39.43M
P/E (TTM)
–
Dividend yield
–

Earnings

Quarterly results announced on Form 8-K, Item 2.02

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q1 FY2026
Ended Mar 31, 2026
May 14, 2026After market close$1.40M$-0.08–
Q4 FY2025
Ended Dec 31, 2025
Feb 3, 2026Before market open–––
Q3 FY2025
Ended Sep 30, 2025
Nov 6, 2025Before market open$600.00K$-0.11–
Q2 FY2025
Ended Jun 30, 2025
Aug 7, 2025After market close$18.30M$-0.08–
Q4 FY2024
Ended Dec 31, 2024
Mar 17, 2025After market close$7.60M$-0.11–
Q3 FY2024
Ended Sep 30, 2024
Nov 12, 2024After market close$49.40M$0.04–
Q2 FY2024
Ended Jun 30, 2024
Aug 6, 2024After market close$300.00K$-0.18–
Q1 FY2024
Ended Mar 31, 2024
May 9, 2024After market close$500.00K$-0.27–
Q4 FY2023
Ended Dec 31, 2023
Mar 13, 2024Before market open–––
Q3 FY2023
Ended Sep 30, 2023
Nov 1, 2023After market close–––
Q2 FY2023
Ended Jun 30, 2023
Aug 8, 2023After market close–––
Q1 FY2023
Ended Mar 31, 2023
Apr 26, 2023After market close–––

Company guidance

Outlook given with results on May 14, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
total operating expensesGAAP2026$110.00M to $130.00MNew
non-GAAP total operating expensesnon-GAAP2026$100.00M to $120.00MNew

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Sangamo Therapeutics filed with the SEC